Market Opportunity Female urinary incontinence is addressed with an in-home, FDA-cleared conservative device, suggesting strong demand there is room to expand sales to clinics, hospitals, and direct-to-consumer channels while highlighting the in-home treatment advantage for patient adherence.

Clinical Validation Stock the conversation with published trial outcomes and FDA clearance to build credibility with payers, providers, and patients, and identify opportunities to partner on registry studies or real-world evidence programs to strengthen adoption.

Expansion Momentum Recent next-generation Flyte System launch and ongoing funding rounds signal growth velocity as a differentiator; leverage this momentum to secure multi-site deployments, partnerships with women's health networks, and expansion into new markets.

Strategic Partnerships Board additions and investor activity point to potential collaboration with healthcare systems, clinicians, and distributors; approach with joint-venture pilots, training collaborations, and co-marketing agreements to accelerate adoption.

Financial & Funding Signals Visible seed and seed-plus funding alongside modest revenue suggests opportunity to target early-adopter clinics and specialty centers for pilot programs, later-scale with value-based pricing discussions and payer engagement.